Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors

Mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic modalities however, there are increasing opportu...

Descripción completa

Detalles Bibliográficos
Autores principales: Quadri, Iman, Reneau, John C., Hanel, Walter, Chung, Catherine G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654973/
https://www.ncbi.nlm.nih.gov/pubmed/38022633
http://dx.doi.org/10.3389/fimmu.2023.1291259
_version_ 1785136726043262976
author Quadri, Iman
Reneau, John C.
Hanel, Walter
Chung, Catherine G.
author_facet Quadri, Iman
Reneau, John C.
Hanel, Walter
Chung, Catherine G.
author_sort Quadri, Iman
collection PubMed
description Mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic modalities however, there are increasing opportunities to exploit the current understanding of pathophysiologic mechanisms of MF/SS for treatment. This review summarizes recent advances in the treatment of MF/SS, with a focus on monoclonal antibodies, immunotherapies, and Janus kinase (JAK) inhibitors, including ongoing clinical trials.
format Online
Article
Text
id pubmed-10654973
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106549732023-01-01 Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors Quadri, Iman Reneau, John C. Hanel, Walter Chung, Catherine G. Front Immunol Immunology Mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic modalities however, there are increasing opportunities to exploit the current understanding of pathophysiologic mechanisms of MF/SS for treatment. This review summarizes recent advances in the treatment of MF/SS, with a focus on monoclonal antibodies, immunotherapies, and Janus kinase (JAK) inhibitors, including ongoing clinical trials. Frontiers Media S.A. 2023-11-03 /pmc/articles/PMC10654973/ /pubmed/38022633 http://dx.doi.org/10.3389/fimmu.2023.1291259 Text en Copyright © 2023 Quadri, Reneau, Hanel and Chung https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Quadri, Iman
Reneau, John C.
Hanel, Walter
Chung, Catherine G.
Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
title Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
title_full Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
title_fullStr Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
title_full_unstemmed Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
title_short Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
title_sort advancements in the treatment of mycosis fungoides and sézary syndrome: monoclonal antibodies, immunotherapies, and janus kinase inhibitors
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654973/
https://www.ncbi.nlm.nih.gov/pubmed/38022633
http://dx.doi.org/10.3389/fimmu.2023.1291259
work_keys_str_mv AT quadriiman advancementsinthetreatmentofmycosisfungoidesandsezarysyndromemonoclonalantibodiesimmunotherapiesandjanuskinaseinhibitors
AT reneaujohnc advancementsinthetreatmentofmycosisfungoidesandsezarysyndromemonoclonalantibodiesimmunotherapiesandjanuskinaseinhibitors
AT hanelwalter advancementsinthetreatmentofmycosisfungoidesandsezarysyndromemonoclonalantibodiesimmunotherapiesandjanuskinaseinhibitors
AT chungcatherineg advancementsinthetreatmentofmycosisfungoidesandsezarysyndromemonoclonalantibodiesimmunotherapiesandjanuskinaseinhibitors

Ejemplares similares